Zeyao Zhu1,2, Zhenguang Ying2, Meiqi Zeng1, Qiang Zhang1,3, Guiqing Liao4, Yunliu Liang2, Chunman Li2, Chengfei Zhang1,5, Xia Wang2, Weipeng Jiang1, Ping Luan6, Ou Sha7,8. 1. School of Dentistry, Shenzhen University Health Science Center, Shenzhen, China. 2. School of Basic Medical Sciences, Shenzhen University Health Science Center, Shenzhen, China. 3. The Shenzhen Stomatology Hospital, Shenzhen, China. 4. Department of Oral and Maxillofacial Surgery, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, China. 5. Faculty of Dentistry, University of Hong Kong, Hong Kong, China. 6. School of Basic Medical Sciences, Shenzhen University Health Science Center, Shenzhen, China. luanping@szu.edu.cn. 7. School of Dentistry, Shenzhen University Health Science Center, Shenzhen, China. shaou@szu.edu.cn. 8. School of Basic Medical Sciences, Shenzhen University Health Science Center, Shenzhen, China. shaou@szu.edu.cn.
Abstract
BACKGROUND: Tongue squamous cell carcinoma (TSCC) is a common type of oral cancer, with a relatively poor prognosis and low post-treatment survival rate. Various strategies and novel drugs to treat TSCC are emerging and under investigation. Trichosanthin (TCS), extracted from the root tubers of Tian-Hua-Fen, has been found to have multiple biological and pharmacological functions, including inhibiting the growth of cancer cells. Granzyme B (GrzB) is a common toxic protein secreted by natural killer cells and cytotoxic T cells. Our group has reported that TCS combined with GrzB might be a superior approach to inhibit liver tumor progression, but data relating to the use of this combination to treat TSCC remain limited. The aim of this study was to examine the effectiveness of TCS on TSCC processes and underlying mechanisms. METHODS: First, we screened the potential antitumor activity of TCS using two types of SCC cell lines. Subsequently, a subcutaneous squamous cell carcinoma xenograft model in nude mice was established. These model mice were randomly divided into four groups and treated as follows: control group, TCS treatment group, GrzB treatment group, and TCS/GrzB combination treatment group. Various tumorigenesis parameters, such as Ki67, PCNA, caspase-3, Bcl-2 and VEGFA, et al., were performed to determine the effects of these treatments on tumor development. RESULTS: Screening confirmed that the SCC25 line exhibited greater sensitivity than the SCC15 line to TCS in vitro studies. TCS or GrzB treatment significantly inhibited tumor growth compared with the inhibition seen in the control group. The TCS/GrzB combination inhibited tumor growth more than either drug alone. TCS treatment inhibited tumor proliferation by downregulating Ki67 and Bcl2 protein expression while accelerating tumor apoptosis. In the TCS/GrzB-treated group, expression of Ki67 was further downregulated, while the level of activated caspase-3 was increased, compared with their expression in either of the single drug treatment groups. CONCLUSION: These results suggest that the TCS/GrzB combination could represent an effective immunotherapy for TSCC.
BACKGROUND:Tongue squamous cell carcinoma (TSCC) is a common type of oral cancer, with a relatively poor prognosis and low post-treatment survival rate. Various strategies and novel drugs to treat TSCC are emerging and under investigation. Trichosanthin (TCS), extracted from the root tubers of Tian-Hua-Fen, has been found to have multiple biological and pharmacological functions, including inhibiting the growth of cancer cells. Granzyme B (GrzB) is a common toxic protein secreted by natural killer cells and cytotoxic T cells. Our group has reported that TCS combined with GrzB might be a superior approach to inhibit liver tumor progression, but data relating to the use of this combination to treat TSCC remain limited. The aim of this study was to examine the effectiveness of TCS on TSCC processes and underlying mechanisms. METHODS: First, we screened the potential antitumor activity of TCS using two types of SCC cell lines. Subsequently, a subcutaneous squamous cell carcinoma xenograft model in nude mice was established. These model mice were randomly divided into four groups and treated as follows: control group, TCS treatment group, GrzB treatment group, and TCS/GrzB combination treatment group. Various tumorigenesis parameters, such as Ki67, PCNA, caspase-3, Bcl-2 and VEGFA, et al., were performed to determine the effects of these treatments on tumor development. RESULTS: Screening confirmed that the SCC25 line exhibited greater sensitivity than the SCC15 line to TCS in vitro studies. TCS or GrzB treatment significantly inhibited tumor growth compared with the inhibition seen in the control group. The TCS/GrzB combination inhibited tumor growth more than either drug alone. TCS treatment inhibited tumor proliferation by downregulating Ki67 and Bcl2 protein expression while accelerating tumor apoptosis. In the TCS/GrzB-treated group, expression of Ki67 was further downregulated, while the level of activated caspase-3 was increased, compared with their expression in either of the single drug treatment groups. CONCLUSION: These results suggest that the TCS/GrzB combination could represent an effective immunotherapy for TSCC.
Entities:
Keywords:
Apoptosis; Granzyme B (GrzB); Oral squamous cell cancer (OSCC); Tongue squamous cell cancer (TSCC); Trichosanthin (TCS)
Authors: Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin Journal: Int J Cancer Date: 2010-12-15 Impact factor: 7.396
Authors: Ou Sha; David Tai-Wai Yew; Eric Yu-Pang Cho; Tzi-Bun Ng; Lin Yuan; Wing-Hang Kwong Journal: Neurotox Res Date: 2009-10-23 Impact factor: 3.911
Authors: Anna Carolina Omena Vasconcellos Le Campion; Camila Maria Beder Ribeiro; Ronir Raggio Luiz; Francisco Feliciano da Silva Júnior; Herbert Charles Silva Barros; Karine de Cássia Batista Dos Santos; Stefania Jeronimo Ferreira; Lucio Souza Gonçalves; Sonia Maria Soares Ferreira Journal: Int J Dent Date: 2017-05-30
Authors: Zhimeng Yao; Liang Du; Min Xu; Kai Li; Haipeng Guo; Guodong Ye; Dianzheng Zhang; Robert P Coppes; Hao Zhang Journal: Front Oncol Date: 2019-08-27 Impact factor: 6.244